Expertise in
9
conditions

Aurelien Marabelle

Gustave Roussy
Villejuif, FR 
Expertise in
9
conditions
Gustave Roussy
Villejuif, FR 

Overview

Aurelien Marabelle practices practicing medicine in Villejuif, France.

Ms. Marabelle is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Melanoma, Non-Small Cell Lung Cancer (NSCLC), Neuroblastoma, and Lung Cancer.

She is actively involved in clinical research, co-authoring 299 peer reviewed articles and participating in 8 clinical trials.

Gender

Female

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Combination product
Study Drug: Atezolizumab
Study Phase: Phase 2
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: AN0025, Pembrolizumab
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Enrollment Status: Unknown
Publish Date: March 04, 2024
Intervention Type: Genetic
Study Phase: Not Applicable
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Enrollment Status: Completed
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours
A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours
Enrollment Status: Completed
Publish Date: October 03, 2018
Intervention Type: Drug
Study Phase: Phase 1
Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies
Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies
Enrollment Status: Unknown
Publish Date: August 23, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 7 Less Clinical Trials

299 Total Publications

Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials.
Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 10, 2026

Frequently Asked Questions about Aurelien Marabelle

Is Aurelien Marabelle a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Aurelien Marabelle is classified as an Advanced expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Aurelien Marabelle participate in research or clinical trials?

Yes. Aurelien Marabelle has published 299 articles and abstracts on conditions like Melanoma. You can view a list of Aurelien Marabelle's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Marabelle's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 45 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile